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A B S T R A C T
Aims: Chronic-active antibody mediated rejection (c-aABMR) is a major cause of kidney graft loss. Currently,
little is known about the relation between histopathologic parameters and renal allograft survival.
Methods and results: Between 2008 and 2014, 41 patients with a progressive decrease in renal function were
diagnosed with c-aABMR according to Banﬀ 2015 and followed up for at least 3 years. Clinical and renal biopsy
characteristics were analyzed for association with graft survival.
During follow-up 26 cases lost their graft because of c-aABMR at a median follow up of 40months after
diagnosis.
Cases with v-lesions in their biopsy had a signiﬁcant higher loss of eGFR prior to diagnosis. The total in-
ﬂammation score (r=−0.45 p= .007) and the severity of interstitial ﬁbrosis (r=−0.38 p= .023) were re-
lated to the eGFR at time of biopsy.
Univariate regression analysis showed that eGFR at time of biopsy, total inﬂammation, interstitial ﬁbrosis and
the sum chronicity score were signiﬁcantly related to the risk for graft failure during follow-up. In a multivariate
analysis only the severity of interstitial ﬁbrosis remained associated with decreased graft survival (HR 1.9 per
score point, 95% CI 1.2–2.8, p= .004).
Conclusion: Severity of renal interstitial ﬁbrosis and not inﬂammation predicts graft survival in cases of c-
aABMR.
1. Introduction
Although short-term results of kidney transplantation have im-
proved signiﬁcantly in the last decades, long-term renal allograft sur-
vival has shown little improvement [1,2]. Therefore, the causes that
pose a barrier to long-term renal allograft survival need to be addressed
in order to further the progress in maximizing the lifespan of trans-
planted kidneys [3–5].
A very important barrier, that has only been fully recognized in
recent years, is chronic-active antibody-mediated rejection (c-aABMR).
The clinical hallmark of c-aABMR is progressive loss of allograft func-
tion with nephrotic range proteinuria. Chronic-aABMR is now regarded
as one of the most important contributors to late renal allograft failure
[6,7]. The prognosis of c-aABMR is very poor with most patients
reaching graft failure within 2–3 years after diagnosis [7–11]. Treat-
ment of c-aABMR has become a major unmet need in transplant
nephrology as there are currently no established eﬀective treatment
protocols available [12–14].
Surprisingly, it is largely unknown whether factors such as renal
histomorphology or clinical parameters are associated with renal allo-
graft survival in patients with c-aABMR. Identiﬁcation of these key
parameters could be of relevance for stratiﬁcation of patients in future
clinical trials or to decide whether or not to treat a patient with c-
aABMR of the kidney allograft.
Previous studies have indicated that cases with a higher degree of
microvascular inﬂammation may be associated with a better response
to therapy and that a compound chronicity score in cases of transplant
glomerulopathy predisposes for poorer allograft survival [15,16].
However, these results were not obtained in clearly Banﬀ-deﬁned co-
horts of c-aABMR patients receiving an identical therapeutic interven-
tion. In this study, the relation between histomorphologic lesions ac-
cording to Banﬀ 2015 criteria and graft survival were analyzed in a
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well-deﬁned group of patients with c-aABMR with a minimum follow
up of 3 years or until graft failure was reached.
2. Objective
To deﬁne prognostic histopathology parameters for the risk of graft
loss in cases with c-aABMR
3. Material and methods
3.1. Study population
We retrospectively included 41 renal transplant patients who had a
biopsy proven diagnosis of c-aABMR between October 2008 and
December 2014. No selection was made for inclusion in this study other
than having a histologically proven diagnosis of c-aABMR. Time of last
follow-up was December 2017. All patients underwent a for cause
biopsy at least 1 year post transplantation due to a progressive decline
in renal function. Renal biopsies were scored according to the Banﬀ ‘15
criteria [17] by 2 independent experienced renal pathologists reaching
consensus on the severity of the diﬀerent lesions in all cases. In ac-
cordance with the Banﬀ ‘15 criteria, the biopsies showing all histolo-
gical criteria for c-aABMR but without detectable DSA were included
though designated as suspicious for c-aABMR.
The Banﬀ lesions could be fully assessed in 35 of 41 patients.
Immunohistochemical staining for C4d was not available in 1 patient.
Following our local protocol, all patients with c-aABMR were ad-
ministered three doses of 1 g intravenous MP over a 3 day period
combined with a single dose of intravenous immunoglobulins (1 g/kg
body weight) on the second day of treatment [18]. Renal allograft
function was assessed on the basis of estimated glomerular ﬁltration
rate (eGFR in mL/min/1.73m2). All eGFR measurements between one
year prior to treatment and one year after treatment were included to
calculate the decrease in eGFR within a given period of time. Cases
included had at least 5 measurements of eGFR at regular intervals in the
year before and after diagnosis of c-aABMR. Allograft failure was de-
ﬁned by the need for starting dialysis treatment or kidney re-
transplantation.
The local medical ethical committee approved the study (april 16th
2015;MEC-2015-222) and humans involved in this study were treated
in a manner in accordance with the Declaration of Helsinki and the
Declaration of Istanbul. All patients gave their written informed consent
for participation in this study.
3.2. Characterization of anti-HLA antibodies
All patients were transplanted with a CDC negative crossmatch. All
sera prior to treatment were screened for the presence of donor-speciﬁc
antibodies against HLA (DSA). Patient serum samples were screened
within a 3month time period before or after diagnostic biopsy for the
presence or absence of HLA antibodies using the Lifecodes Lifescreen
Deluxe (LMX) kit, according to the manufacturer's manual (Immunocor
Transplant Diagnostics Inc. Stamford, CT, USA). Samples were con-
sidered positive for either HLA class I (HLA-A or HLA-B or HLAeC) or
HLA class II (HLA-DQ or HLA-DR) antibodies were further analyzed
with a Luminex Single Antigen assay, using LABscreen HLA class I and
class II antigen beads (One Lambda Canoga Park, GA, USA).
3.3. Statistical analysis
Normally distributed data are expressed as mean +/− SD, non-
normally distributed data as median with range. A p-value of< 0.05
was considered statistically signiﬁcant.
Death-censored graft survival was assessed by Kaplan-Meier ana-
lysis with log-rank statistics for diﬀerence between strata. For this
analysis the histomorphologic lesions were analyzed dichotomously (if
possible, see results). Cases in which lesions were scored as minimal to
mild (0–1) were compared to cases in which lesions were scored as
moderate to severe (2–3). Both v-lesions and C4d staining were scored
as either being present or absent.
Univariate and multivariate logistic regression analysis was per-
formed to identify an association between histomorphological lesions
(as continuous variables) and clinical variables with graft survival.
Variables with a p-value of< 0.1 were considered for a multivariate
proportional hazard analysis in a forward stepwise manner. Statistical
analysis was performed with software IBM SPSS statistics 21.
4. Results
4.1. Clinical characteristics
The demographic and clinical characteristics at time of for cause
biopsy are summarized in Table 1. Time to biopsy from the moment of
transplantation showed a median of 76 (12–218) months. The im-
munosuppressive regimen predominantly consisted of combined ta-
crolimus and mycophenolate mofetil (71%). During the ﬁrst year of
follow up no deaths occurred but 3 patients progressed to allograft
failure. A total of 26 cases lost their renal allograft as a result to c-
aABMR at a median follow up of 40months after diagnosis by renal
biopsy.
Twenty-six percent of c-aABMR cases had a previous biopsy proven
acute rejection (BPAR). The vast majority (85%) of the BPAR was T-cell
mediated rejection (TCMR) and occurred within the ﬁrst months after
transplantation. Proteinuria varied substantially from marginally pre-
sent to several gram/L.
4.2. Histomorphological characteristics
The scores of the lesions of the renal biopsies (n=35), graded by
the Banﬀ criteria, are shown in Fig. 1. In 6 cases there were an in-
suﬃcient number of non-sclerotic glomeruli in the biopsy to fulﬁll the
criteria for scoring according to the Banﬀ classiﬁcation.
All biopsies showed glomerular basement membrane double con-
tours (cg) of which>90% were scored as either cg2 or cg3. In addition,
Table 1
Clinical and immunological characteristics of 41 cases of chronic-active anti-
body mediated rejection.
Age in years median (range) 52 (19–72)
Gender, male % 63.4%
Donor type:
Deceased 29%
Living related 27%
Living unrelated 44%
Previous transplantation % 41.5%
Time to diagnosis in months median (range) 76 (12–218)
Follow up time in months median (range) 27 (8–86)
Number of HLA mismatches, median (range) 3 (1–6)
DSA present, n (%) 17 (43.9%)
Type of DSA:
Anti-HLA class 1 (n=3)
Anti-HLA class 2 (n=15)
Previous biopsy proven acute rejection 26.8%
Proteinuria (g/L) at time diagnosis, median (range) 0.8 (0.1–11.5)
eGFR mL/min/1.73m2, median (range)
1 year before diagnosis 37 (15–78)
Time of diagnosis 30 (15–45)
1 year after diagnosis 30 (8–47)
Immunosuppressive medication (%)
Tacrolimus 81
Cyclosporine 5
Mycophenolate mofetil 90
Prednisone 22
Other 7
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microvascular inﬂammation (MVI) was present in all biopsies with a
high mean MVI of 5. Arteritis (v-lesion) was present in 11 biopsies
(26.8%). Importantly, minimal tubulitis (t1) was only observed in a
minority of cases (31 cases (75.6%) with no tubulitis). A combined
score (chronicity score) of interstitial ﬁbrosis (ci)+ tubular atrophy
(ct)+ total inﬂammation (ti) has been identiﬁed as a predictor of renal
allograft loss in cases with transplant glomerulopathy [16] and was
therefore calculated for all cases.
Of note, analysis showed that cases with c-aABMR and arteritis (v-
lesion) showed a signiﬁcantly faster decline in graft function in the year
before treatment. The decline in function of these patients was
−16.2 mL/min/1.73m2 compared −9.8mL/min/1.72m2 in patients
without arteritis(p < .01). However, c-aABMR cases with arteritis did
not diﬀer signiﬁcantly from those without arteritis with respect to all
other histomorphological characteristics (data not shown).
In addition, an association was found for total inﬂammation score
(r=−0.45 p= .007) and severity of interstitial ﬁbrosis (r=−0.38
p= .023) with graft function (eGFR) at time of biopsy. None of the
Banﬀ lesions related with the degree of proteinuria at time of biopsy. As
has been previously published, no relation between the presence of DSA
in the serum, Banﬀ scores and graft survival could be found [19].
4.3. Clinical and histomorphological characteristics in relation to graft
survival
For Kaplan-Meier analysis, cases were divided into low or high
histomorphological scores according to a minimal-to-mild score (0–1)
or a moderate-to-severe score (2–3). This analysis could not be per-
formed for cg, mm and microvascular inﬂammation (either for glo-
merulitis, peritubular capillaritis or combined MVI score) as the large
majority of cases showed high scores (2 or 3) for these items (Fig. 1).
For the remaining lesions higher scores for tubular atrophy (ct),
interstitial ﬁbroses (ci), inﬂammation (i) and total inﬂammation (ti)
were associated with decreased graft survival (Fig. 2). However, in-
terstitial ﬁbrosis signiﬁcantly correlated with inﬂammation scores, both
inﬂammation in non-scarred tissue (i) and total inﬂammation (ti)(re-
spectively r=0.54= 0.001 and r=0.50, p= .002). In addition, as
expected, the degree of interstitial ﬁbrosis correlated strongly with
tubular atrophy (r=0.64 p < .001).
Univariate regression analysis of the Banﬀ lesions showed that total
inﬂammation, interstitial ﬁbrosis and chronicity score were sig-
niﬁcantly related to the risk for graft failure during follow-up (Table 2).
Univariate regression analysis of clinical parameters (Table 1) did not
show any variable signiﬁcantly associated with graft failure except for
eGFR at time of biopsy (HR 0.93 per mL/min eGFR, 95% CI 0.88–0.98,
p= .021).
Within the multivariate proportional hazards regression analysis,
including the univariate signiﬁcant Banﬀ lesions and eGFR at time of
biopsy, only the degree of interstitial ﬁbrosis (HR 1.9 per score point,
95% CI 1.2–2.8, p= .004) was independently associated with graft loss
censored for death.
5. Discussion
In this study we have analyzed the association of clinical char-
acteristics and Banﬀ lesions in patients with biopsy proven c-aABMR in
relation to graft survival.
Most importantly, chronic interstitial ﬁbrosis was the dominant
factor associated with graft survival after the diagnosis of c-aABMR.
This ﬁnding is line with two recent publications which showed that a
higher sum chronicity score was associated with inferior graft survival
of patients with a diagnosis of transplant glomerulopathy and c-aABMR
[16,20].
Previously, proteinuria has been identiﬁed in general as a potential
Fig. 1. Banﬀ scores in the c-aABMR biopsies. Inﬂammation(i), total inﬂammation (ti), tubulitis (t), v (arteritis/v-lesions), glomerulitis (g), peritubular capillaritis
(ptc), C4d positive in ptc or glomerulus (glom), interstitial ﬁbrosis (ci), tubular atrophy (ct), arterial intimal thickening (cv), arteriolar hyalinosis (ah), alternative
arteriolar hyalinosis score (aah), mesangial thickening (mm).
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predictor of poor renal survival. More severe proteinuria might indicate
more severe structural damage of the glomerulus and increased in-
ﬂammation. However, we could not relate the degree of proteinuria
with any of the Banﬀ lesions or the risk for allograft loss. This lack of
association may be in part caused by the fact that the proteinuria was
not normalized for the urine creatinine concentration. However, even if
we compared the groups of patients with low proteinuria (< 0.5 g/L) to
high proteinuria (> 0.5 g/L) we could not ﬁnd a signiﬁcant relation
with graft survival (data not shown).
As previously suggested by Kahwaji et al., higher MVI scores may be
associated with superior response to therapy [15]. Others did ﬁnd a
decrease in MVI score after treatment but without a relation to clinical
response [21]. This observation could not be conﬁrmed in our study as
the microvascular inﬂammation in the glomeruli and peritubular ca-
pillaries, either separately or combined, was not associated with graft
survival. In a recent publication by Viglietti et al., the peritubular ca-
pillaritis Banﬀ score was a signiﬁcant factor in a multivariate model to
predict outcome in cases of acute ABMR [22]. However, it should be
noted that this result cannot be easily translated to this study as only
18% of the cases in their study had chronic allograft glomerulopathy
and the average IFTA score was 1 (respectively 100% and 1.5 in this
study). In addition, only a few cases in our study actually had a low MVI
which reduces the discriminatory power of this criterion.
As described recently, arteritis can be found in almost half of cases
with aABMR (coined antibody-mediated vascular rejection) and is as-
sociated with decreased allograft survival as compared to aABMR
without arteritis [23]. In our study, arteritis was present in about 1/3 of
patients with c-aABMR. Allograft function declined much more rapidly
in the cases with arteritis but ultimately did not result in more graft
loss. As all cases received steroids and IVIG this may indicate a better
response to therapy when v-lesions are present. The origin of the v-
lesions in the c-aABMR cases is not clear as it cannot be established with
certainty whether arteritis represents humoral rejection on the level of
the larger vessels or a true T cell-mediated immune response. The latter
is not supported by the presence of signiﬁcant tubulitis in the renal
biopsies, but may explain a more favorable response to high dose
steroids.
This study has some obvious limitations as it is of retrospective
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Fig. 2. Kaplan-Meier curves of kidney transplant survival for
cases with c-aABMR after the diagnosis and treatment with
IVIG/MP. Cases were divided in a low and high score group
based on their speciﬁc histomorphology scores (low= absent
to low score, high=moderate to severe score). Total in-
ﬂammation (ti) high n=29, low n=6; inﬂammation (i),
high n=22, low n=13; tubular atrophy (ct), high n=8 and
low n=27; interstitial ﬁbrosis (ci),high n=19, low n=16;
v-lesions, no n=24, present n=11; arteriolar hyalinosis
(ah), high n=12, low n=23; alternative arteriolar hyali-
nosis score (aah), high n=10, low n=25; C4d score posi-
tive n=23, negative n=17. P-values were calculated by
log-rank statistical analysis pairwise over diﬀerent strata.
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nature with a relatively small group of patients treated for c-aABMR.
However, the cases included are histologically well-deﬁned as c-aABMR
and have all received a similar treatment schedule with a largely similar
basic immune suppressive regime consisting of a calcineurin inhibitor
and mycophenolate mofetil. The uniform treatment schedule in this
study is also a limitation as other treatment regimens may show dif-
ferent relations for outcome with clinical variables and Banﬀ scores. In
support of our ﬁndings, the relation between interstitial ﬁbrosis and
graft survival was also observed in 2 studies with a heterogeneous
treatment regimen for c-aABMR [16,20]. This consistency may not be
surprising as the degree of interstitial ﬁbrosis is a commonly found
predictor of progressive loss of diseased native kidneys. However, the
degree of microvascular inﬂammation did not predict graft survival,
indicating that not inﬂammation by itself but the resulting interstitial
ﬁbrosis is the most important feature of chronic humoral rejection. It is
therefore of interest to study more closely the type and functionality of
the graft inﬁltration immune cells in relation to the degree of interstitial
ﬁbrosis. Circulating activated immune cells (e.g.NK-cells) poorly cor-
relate with c-aABMR [24] but preliminary data indicate that in parti-
cular an inﬂux of activated CD8 T cells in the interstitium is harmful in
this respect [25].
The renal biopsies were performed due to a progressive decrease in
eGFR which is reﬂected in the high scores for glomerulopathy and
microvascular inﬂammation. It seems therefore likely that milder or
subclinical forms of c-aABMR were not included in this study [26].
Therefore, the associations found between Banﬀ lesions, clinical char-
acteristics and graft survival may not apply for those cases and cases of
acute ABMR.
In conclusion, the result of this study shows that the degree of in-
terstitial ﬁbrosis, but not the indicators of inﬂammation, is associated
with graft survival. These ﬁndings may be important for risk stratiﬁ-
cation in clinical trials for c-aABMR and clinical decision making.
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